CAR-T cells - International Biopharmaceutical Industry

Current Edition

Issue 9, Volume 3

Current Features

Issue 9, Volume 3

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

news

Gilead’s Kite Exits China Cell Therapy Joint Venture with Fosun Pharma

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the 50-50 cell-therapy-focused joint venture wi...

23 September 2024 news CAR-T cells | Cell and Gene Therapy

Continue Reading →

Volume 4 Issue 3

Are We Nearly There Yet? The Ongoing Journey of CAR-T Cell Therapies

CAR-T cells have a genetically engineered T-cell receptor (TCR) that directs their binding to cancer cells. In first-generation CARs, the TCR was engineered to expres...

31 August 2021 Volume 4 Issue 3 CAR-T cells | development

Continue Reading →